Methylthioninium chloride controlled-release tablet - Cosmo

Drug Profile

Methylthioninium chloride controlled-release tablet - Cosmo

Alternative Names: CB-17-01; Methylene blue delayed-release - Cosmo; Methylene blue MMX®; Methylene blue tablet - Cosmo

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Cosmo Pharmaceuticals
  • Class Diagnostic agents; Dimethylamines; Phenothiazines; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Colorectal cancer

Most Recent Events

  • 01 Dec 2014 Cosmo completes a phase II trial in Colorectal cancer diagnosis in Italy (NCT02295774)
  • 11 Dec 2013 Phase-III clinical trials in Colorectal cancer in Belgium, Germany, Italy, Netherlands (PO)
  • 22 Oct 2012 Efficacy and adverse events data from a phase II trial in Colorectal cancer released by Cosmo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top